CVS Caremark, FTC settle insulin pricing case for $13B

Ella Jeffries / beckershospitalreview - The Federal Trade Commission reached a settlement with CVS Caremark that requires the pharmacy benefit manager to change its business practices as part of the agency’s antitrust case alleging the PBM inflated insulin list prices through rebate practices. …

AI Summary: CVS Caremark agreed to a $13 billion settlement with the Federal Trade Commission to resolve allegations tied to its handling of insulin pricing and related business practices. The deal includes a large cash payment and operational changes designed to address the FTC’s concerns, and now awaits court approval and implementation details.